363 related articles for article (PubMed ID: 7690326)
1. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
2. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
3. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
Lipford GB; Bauer S; Wagner H; Heeg K
Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
Peng S; Frazer IH; Fernando GJ; Zhou J
Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
[TBL] [Abstract][Full Text] [Related]
5. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.
Feltkamp MC; Vreugdenhil GR; Vierboom MP; Ras E; van der Burg SH; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1995 Sep; 25(9):2638-42. PubMed ID: 7589138
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope.
Gao L; Walter J; Travers P; Stauss H; Chain BM
J Immunol; 1995 Dec; 155(12):5519-26. PubMed ID: 7499833
[TBL] [Abstract][Full Text] [Related]
8. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
Castellanos MR; Hayes RL; Maiman MA
Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
[TBL] [Abstract][Full Text] [Related]
9. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
11. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
12. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E
Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358
[TBL] [Abstract][Full Text] [Related]
13. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
14. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
Préville X; Ladant D; Timmerman B; Leclerc C
Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
[TBL] [Abstract][Full Text] [Related]
15. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A; Schirmbeck R; Reimann J
Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
[TBL] [Abstract][Full Text] [Related]
18. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
[TBL] [Abstract][Full Text] [Related]
19. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope.
Vierboom MP; Feltkamp MC; Neisig A; Drijfhout JW; ter Schegget J; Neefjes JJ; Melief CJ; Kast WM
J Immunother; 1998 Nov; 21(6):399-408. PubMed ID: 9807734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]